Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that its CEO Leo Lee, will present at the Finance News Network (FNN) CEO Showcase virtual event on Tuesday 25 August 2020 at 12:55pm (AEST). The event is primarily attended by Australian-based retail investors and advisors.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30 June 2020.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's Secretome technology platform, Sygenus, in the U.S.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Kyocera Corporation (Kyocera, TYO:6971) has signed a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide an update on initiation of challenge study in poultry with the recently developed bromelain-based formulation (ANR-pf).
During the quarter, Regeneus Ltd (ASX:RGS) received notification from Kyocera Corporation (TYO:6971) that its lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis (Progenza OA) had passed Kyocera's due diligence process.
While focussing financial resources on development of GaRP, Anatara has been evaluating development, in collaboration with third parties, additional dosage forms for piglets and to utilise Anatara's intellectual property in other species including in-feed formulations for piglets, formulations for aquaculture and formulations for poultry.
